Pss29 - Secukinumab Versus Etanercept for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2529
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pss35 - Secukinumab Versus Ustekinumab for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms42 - Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms45 - Cost Per Responder Analysis Following a 48-Week Psoriatic Arthritis Treatment With Secukinumab Versus Adalimumab From the Portuguese Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms29 - Secukinumab Versus Adalimumab in the Treatment of Ankylosing Spondylitis: A Cost Per Responder Analysis Among 52 Weeks From a Tunisian Perspective.

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms28 - Secukinumab Versus Infliximab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss31 - Cost Per Responder of Secukinumab Compared to Other Biologics in Moderate-To-Severe Plaque Psoriasis From the Private Payer Perspective in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms27 - Secukinumab Versus Adalimumab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms31 - Secukinumab as a More Eeficient Alternative for Ankylosing Spondylitis Treatment: A Cost Per Responder Analysis From Korean Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss33 - Secukinumab as First Biologic Treatment: A Cost Per Responder Analysis Compared With Licensed Biologics, for Moderate to Severe Psoriasis in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy